Efficacy and Safety of Covid-19 Vaccine in Cardiac Patients

N/AUnknownNCT05348629

Mina sobhi said fam50 enrolled

Overview

Efficacy and safety of covid-19 vaccine in Cardiac patients

investigate the efficacy and safety of covid-19 vaccine in cardiac patients and its possible assocciated morbidity

Study Type

OBSERVATIONAL

Enrollment

Conditions

COVID-19 Vaccine

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects diagnosed as STEMI undergo PPCI as (Fourth universal definition of myocardial infarction (2018) Kristian Thygesen) 10 * with age range from 18 to 80 years after 1 month of STEMI . Exclusion Criteria: * Patients with previous covid infection confirmed by swap or CT chest or ICU addmision. * Patients with previous covid infection confirmed by qualitative antibdy test . * Patients with history of anaphylaxis to any component of the vaccine should not take it . * patients with febrile illness or acute , ongoing infection . * immunosuppressive diseases .

Locations (2)

Assiut University

Asyut, Egypt

RECRUITING

Assiut university

Asyut, Egypt

RECRUITING

Outcomes

Primary Outcomes

all cause mortality

Time frame: one year

Myocardial infarction

Time frame: one year

stent thrombosis

Time frame: one year

Secondary Outcomes

Cardiovascular death. Cardiovascular death. Cardiovascular death.Cardiovascular death. cardiovascular death

Cardiovascular death.

Time frame: one year

heart failure hospitalization

Time frame: one year

infection by covid-19

Time frame: one year

anaphylaxis required hospitalization

Time frame: one year

Central Contacts

Mina Fam, Residuant

CONTACT

+201122035368 minassfam@yahoo.com

Aly Tohamy, Lecturer

CONTACT

+201006258877 Ali.tohamy@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.